About
The 13th IMPACCT Real-World Evidence Summit
As the CMS introduces new guidance for RWD studies, the FDA announces a RWE Center to promote its use in regulatory decision-making, and RWD becomes more accessible, investment is pouring into RWE generation. It is evident RWE will play an increasingly pivotal role in the drug development lifecycle, but questions still remain for the experts optimizing and applying RWE.
As the only industry meeting uniting RWE experts the 13th IMPACCT Real-World Evidence Summit offers you the opportunity to consolidate, innovate and optimize your RWE strategy at all stages of the drug development lifecycle.
Connect with 140+ industry pioneers from Pfizer, AstraZeneca, Alexion, Moderna, and Boehringer Ingelheim, as they share first-hand case studies in fortifying data quality, validating use of AI and predictive modeling in data analysis, leveraging RWE to support regulatory submissions and more.
Access the Brand-New Agenda
140+ industry experts
26+ world-class speakers
3 days of content-led sessions
Latest industry case-studies and examples
Discover What's in Store for 2025:
Explore cutting-edge tools including AI modeling and tokenization to enrich clinical data, extend follow-up, and support long-term evidence needs
Discover how to design studies and structure data that meet payer and HTA expectations for credibility and transparency
Understand how to connect disparate datasets across markets and systems, to deliver impactful, scalable, and privacy-preserving RWE insights
Learn how to apply RWD from early clinical development through to post-market access, to streamline decision-making and reduce time to market
Hear From Your Peers:
“There were presentations from various expert stakeholders, small group discussions and networking sessions”
Past Attendee, Executive Director, Health Economic & Outcomes Research, Pfizer
“The diversified knowledge and rich experience of the speakers, made the event very enjoyable and educational”
Past Attendee, Senior Director, Chiesi Farmaceutici
“The program featured state-of-the art presentations addressing challenges anyone working in the health data
space and evidence generation will be facing”
Past Attendee, Director Value & Access, Eli Lilly & Co
